Compare KN & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KN | ADMA |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2013 | 2012 |
| Metric | KN | ADMA |
|---|---|---|
| Price | $30.13 | $11.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $22.33 | ★ $25.67 |
| AVG Volume (30 Days) | 569.3K | ★ 7.3M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.94 | N/A |
| EPS | 0.50 | ★ 0.60 |
| Revenue | ★ $593,200,000.00 | $42,219,783.00 |
| Revenue This Year | $9.40 | $27.46 |
| Revenue Next Year | $6.98 | $22.11 |
| P/E Ratio | $62.48 | ★ $18.33 |
| Revenue Growth | 7.17 | ★ 43.85 |
| 52 Week Low | $15.43 | $7.21 |
| 52 Week High | $31.95 | $25.67 |
| Indicator | KN | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 62.17 | 50.33 |
| Support Level | $23.97 | $7.21 |
| Resistance Level | N/A | $16.61 |
| Average True Range (ATR) | 1.06 | 0.49 |
| MACD | 0.25 | 0.36 |
| Stochastic Oscillator | 70.08 | 97.21 |
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.